Activating estrogen receptor mutations (ESR1 mutations) are acquired through prior aromatase inhibitor therapy for ABC (7), with circulating tumor DNA analysis demonstrating that the mutations are present in 15% to 40% of patients treated with prior aromatase inhibition (8, 9). The gene discussed is CYP19A1; the disease is neoplasm.